Benefits
Supports normal daytime urinary frequency
In a randomized, double-blind trial of 150 adults with overactive bladder symptoms, two capsules daily for 8 weeks lowered daytime urination to about 7.7 times a day versus about 11.0 on placebo, the primary outcome named in the paper's methods. The maker funded the trial, and the trial was registered after enrollment had ended.
Supports fewer nighttime trips to urinate
In the same 8 week adult trial, nighttime urination fell to about 2.2 episodes a night versus about 3.1 on placebo, a second registered primary outcome. The blend group started with more nighttime urination than the placebo group (about 4.0 versus 3.4 a night), which complicates the comparison.
Supports bladder control, urgency and daily comfort
Adults taking the blend reported fewer urgency and leakage episodes and better bladder-related quality of life scores than placebo after 8 weeks. These were secondary outcomes; the authors adjusted for repeated time points but did not state a correction across the many outcomes tested.
Supports nighttime bladder control in school-age children
In a placebo-controlled trial in children aged 6 to 14 with bedwetting, 8 weeks of the children's version reduced wet nights versus placebo on the registered primary outcome (between-group p = 0.04), and daytime urgency also fell. Only 41 children completed the trial, and it was funded by the maker.
Bladder function findings in a rat model
In rats whose bladders were made overactive with a chemical irritant, 14 days of the blend by mouth improved bladder filling pressure and voiding measures and normalized several bladder tissue markers compared with untreated rats. This is animal research at a very high dose per body weight and does not show an effect in people.
Mechanism of action
Three-herb combination with a lupeol-standardized Crataeva
The blend pairs Crataeva nurvala stem bark, standardized to the triterpene lupeol, with unstandardized horsetail and Lindera root. The trial authors speculate that it improves the tone of the bladder muscle, but this was not measured in the human trials, and no study has tested which herb drives the reported effects.
Bladder nerve and tissue signaling in rats
In a rat model of an overactive bladder, the blend restored urine levels of nerve growth factors and bladder levels of the pain and stretch sensor TRPV1, Rho kinase and oxidative stress markers, and calmed activity in brain voiding centers, while leaving inflammatory cytokines unchanged. These findings come from animals only.
Horsetail as a traditional mild diuretic
On its own, horsetail is recognized in the EU only as a traditional herbal medicine to increase urine flow, and a small trial in healthy men found a diuretic effect without changes in sodium or potassium excretion. How this action fits with fewer daily urinations in the blend trials is not explained by the studies.
Clinical trials
Randomized, double-blind, placebo-controlled phase 2 trial at two Brisbane centers; two 420 mg capsules once daily with food or cellulose placebo for 8 weeks; registered as NCT02396160 in March 2015, after recruitment (April 2013 to November 2014) but before analysis according to the authors, listing day frequency and nocturia as primary outcomes; the paper's methods state urinary frequency as the primary outcome and base the sample size on day frequency; funded by Seipel Group, which employs co-author Tracey Seipel, the inventor on the formula's US patent (Schoendorfer et al. 2018, BMC Complement Altern Med)
150 adults (59% women, mean age 63.5) with at least two of: daytime frequency of 10 or more, nocturia, urgency or leakage; 142 completed (69 of 75 on the blend, 73 of 75 on placebo).
At week 8, daytime voids were 7.69 versus 10.95 a day and nighttime voids 2.16 versus 3.14 a night (both p < 0.001); urgency and total leakage episodes were also lower (p < 0.01), and quality of life scores improved more than with placebo. The blend group had more nocturia at baseline, the reported odds ratios are unusually extreme (as low as 0.01), and each outcome was analyzed only in people symptomatic for it. Adverse events were 5 on the blend and 8 on placebo, none causing withdrawal.
Randomized, double-blind, placebo-controlled trial; one capsule (40 kg or less) or two capsules (over 40 kg) each morning for 8 weeks; prospectively registered as ACTRN12618000288224 with wet nights per week as the single primary outcome; funded by Seipel Group with an Australian government grant, per the protocol; no author lists a Seipel affiliation; a corrigendum was later published (Schloss et al. 2021, Phytomedicine)
Children aged 6 to 14 with primary bedwetting on at least 3 nights a week, recruited in Australia; 41 completed (16% attrition); the abstract reports 64.6% boys and a mean age of 8.6 years.
The registered primary outcome favored the blend over placebo in a longitudinal between-group analysis (p = 0.04, coefficient -1.12), and the abstract reports that 41.7% of participants improved by two months, without giving the split by group. Urinary urgency fell 18.3% with the blend versus a 3.7% rise with placebo; the abstract gives p = 0.002 for the blend group without saying whether this was a between-group test. The trial was small, the protocol allowed an interim sample-size recalculation (planned 80, registered 62), and adverse event details are not given in the abstract.
Published protocol for the children's trial; documents the per-capsule composition, the weight-based dose, the Australian listing of Urox (AUST L 194355) and Seipel Group funding (Schloss et al. 2019, BMC Pediatr)
Planned 80 children aged 6 to 14 with 3 or more wet nights a week; 8 weeks of capsules then follow-up to week 32.
This is a protocol, not a results paper. It states that Bedtime Buddy is the same formula as Urox dosed for children, sets change in wet nights at week 8 as the primary outcome, and plans an interim analysis after 30 children to recalculate the sample size.
Controlled animal study in 60 female Wistar rats in four groups; bladder overactivity induced by retinyl acetate instilled into the bladder, then Urox 840 mg by gavage once daily for 14 days; funded by the Medical University of Lublin, with no commercial conflicts declared (Zapała et al. 2022, Front Mol Biosci)
Female Wistar rats weighing about 250 g (animal study, not people).
Compared with untreated irritated bladders, the blend lowered basal pressure and the detrusor overactivity index, increased voided volume and bladder compliance, and normalized urine levels of NGF and BDNF and bladder markers such as TRPV1 and Rho kinase. The dose was very high for the animals' body weight, and the results are not human evidence.